Two preprints probe CFTR function across genotypes and carrier states
Back-to-back bioRxiv preprints use large clinical datasets and nasal airway cell measurements to examine how CFTR channel function relates to disease severity and to respiratory symptoms in carriers.
Two preprints posted simultaneously to bioRxiv on 18 June 2026 advance understanding of how cystic fibrosis transmembrane conductance regulator (CFTR) function relates to clinical outcomes across the full spectrum of genotypes and carrier states.
The first preprint, drawing on clinical and functional data from the CFTR2 study — which includes records from 84,418 individuals linked to functional measurements across 289 CFTR genotypes — attempts to define the genotype-to-function-to-phenotype relationship more precisely than prior analyses. The authors report that the relationship between CFTR function and clinical markers such as sweat chloride, lung function, and pancreatic status is complex and, in places, non-linear, challenging simpler models that have previously been used to predict outcomes from genotype alone.
The second preprint investigates CFTR function specifically in CF heterozygotes — individuals carrying one disease-causing CFTR variant. Using nasal epithelial cell measurements from symptomatic and asymptomatic heterozygotes alongside non-carrier controls, the authors examine whether reduced CFTR channel activity might partly explain the elevated prevalence of chronic respiratory symptoms observed in some carriers. The study aims to establish whether CFTR function differs between symptomatic and asymptomatic heterozygotes.
Both manuscripts are preprints that have not yet undergone peer review. They are relevant to researchers working on CFTR biology, to genetic counsellors advising families where carrier status is relevant, and to educators teaching variant interpretation and genotype-phenotype correlation. The CFTR2 resource has been a key tool in variant classification efforts and in supporting regulatory assessment of CFTR modulators.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Cystic fibrosis (CF) is caused by faults in a gene called CFTR. Two new pieces of early-stage research — called preprints, meaning they have not yet been fully checked by independent scientists — look at how well the CFTR protein works in different groups of people.
The first study used information from more than 84,000 people to explore the link between a person's CFTR gene variants, how much the protein works, and how unwell they are. It found that this relationship is more complicated than previously thought.
The second study looked at people who carry just one faulty copy of CFTR — known as carriers or heterozygotes. Most carriers do not develop CF, but some have respiratory symptoms. The researchers measured CFTR activity in nose cells to see whether it differs between those with and without symptoms.
Because these are preprints, the findings may change after expert review. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary sourcePreprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-06-18Clinical and primary cell evidence reveals complex CFTR function-phenotype relationships
-
Preprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-06-18CFTR function in nasal airway cells from symptomatic and asymptomatic CF heterozygotes